NCT07058792 Impact of Medjool Date Consumption on Labor and Delivery Outcomes
| NCT ID | NCT07058792 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cleveland Clinic |
| Condition | Spontaneous Labor |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-02-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2025-02-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed Medjool date randomized trial will help inform clinical practice regarding the utility of Medjool date consumption for labor onset by comparing the incidence of spontaneous labor with the need for labor induction in patients who have been randomized to consume Medjool dates from 34 weeks gestation through the day after delivery day. The study will secondarily investigate the relationship between date consumption and other important labor and delivery outcomes such as length of labor, need for oxytocin, dose of oxytocin and quantitative blood loss at delivery. This study will also explore the association between Medjool date consumption, perinatal hemoglobin levels, and perinatal diet quality. Assessing dietary intake is an essential component of this study to better understand the relationship between medjool date consumption and pregnancy/labor outcomes by controlling for it as a potential confounding factor. Furthermore, assessing dietary intake will provide insight on the impact medjool date consumption has on overall maternal diet quality.
Eligibility Criteria
Inclusion Criteria: * Singleton pregnancy less than 36weeks 0 days gestational age * Age ≥18 years old * Has decision-making capacity and able to provide informed consent for research participation * Able to speak, read and understand English * Planned delivery at a Cleveland Clinic Institution Exclusion Criteria: * Pre-existing medical co-morbidities including hypertension, kidney disease, autoimmune conditions, diabetes * Comorbidities of pregnancy including hypertensive disorders of pregnancy and gestational diabetes * Abnormal genetic (aneuploidy) screening or diagnostic testing * Patients with pregnancies complicated by major fetal anomalies * Multifetal gestation * Delivery at an outside institution * Incomplete delivery data * Planned cesarean delivery * Planned induction of labor prior to 41 weeks
Contact & Investigator
Stacey Ehrenberg, M.D.
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT07058792 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Spontaneous Labor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07058792 currently recruiting?
Yes, NCT07058792 is actively recruiting participants. Contact the research team at patele@ccf.org for enrollment information.
Where is the NCT07058792 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT07058792 clinical trial?
NCT07058792 is sponsored by The Cleveland Clinic. The principal investigator is Stacey Ehrenberg, M.D. at The Cleveland Clinic. The trial plans to enroll 250 participants.